Drucker of Lunenfeld-Tanenbaum Research Institute, University of Toronto, evaluated the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity and explored their potential for new indications
and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia [see ADVERSE REACTIONS ]
In addition, they can help set people up for long-term success by learning portion control, balanced eating, and basic nutrition
Rozengurt, E
If you see a sudden drop in flight time or a big jump in internal resistance, it may be time to reduce the stress on that battery or retire it from high-demand applications
Sarwer, director of the Center for Obesity Research and Education in the Barnett College of Public Health at Temple University, told Flow Space "A lot of these things can be multifactorial." With that said, here are seven unusual side effects of GLP-1 drugs